About Steba Biotech
Steba Biotech is a Luxembourg based biotech company which holds exclusive rights from the Weizmann Institute of Science (WIS, Israel) and Memorial Sloan Kettering Cancer Center (MSKCC, New York), to develop and commercialize drugs and related technologies used in ImPACT (Immune Photo Activated Cancer Therapy).
ImPACT is a potential mainstay cancer therapy that offers a novel platform for the unmet need of organ preserving treatment of solid tumors at the localized and metastatic stage.
ImPACT's innovative approach was developed at the Weizmann Institute by Profs A. Scherz and Y. Salomon. It comprises intravenous delivery of the drug followed by activation in the tumor circulation via optical fibers that have been positioned in the target tissue by image guiding means. This activation results in immediate occlusion of the tumor blood supply followed by self-propagating necrosis of the entire
tumor with minimal collateral damage to surrounding normal tissue. The necrotic cell death triggers antitumor immunity that can be amplified by combining ImPACT with various drugs including checkpoint inhibitors, resulting in regression of remote